Vijay Pande, PhD, is a general partner at Andreessen Horowitz, where he focuses on investments in biopharma and healthcare, and serves on the boards of Apeel Sciences, Asimov, BioAge, Ciitizen, Devoted Health, Freenome, Insitro, Omada, PatientPing, and Rigetti Computing. Pande is also an Adjunct Professor of Bioengineering at Stanford University, where he continues to advise the Pande Lab, focused on tackling challenging problems in chemical biology, biophysics, and biomedicine.

As the founding investor of a16z’s Bio Fund, Pande leads the firm’s investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances applied to industry that take bio beyond healthcare. Op-eds by Pande defining trends and issues in this emerging space have been published by The New York Times, Scientific American, and Forbes, among others.